# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced that the primary study results from its CAHtalyst™ Pediatric Phase ...
Wedbush analyst Laura Chico reiterates Neurocrine Biosciences (NASDAQ:NBIX) with a Outperform and maintains $152 price target.
Kyle Gano, Ph.D., currently Neurocrine's Chief Business Development and Strategy Officer, will succeed him in the CEO role....
New CAHtalyst™ Pediatric and CAHtalyst™ Adult Phase 3 Clinical Study Data in Congenital Adrenal HyperplasiaCAHtalog™ Registry D...
UBS analyst Ashwani Verma maintains Neurocrine Biosciences (NASDAQ:NBIX) with a Buy and raises the price target from $174 to...
Neurocrine Biosciences, Inc. (NASDAQ:NBIX) today announced the publication of data from a post hoc analysis of the Phase 3 KINE...
- CAHtalyst™ Phase 3 Baseline Characteristics Highlight Limitations of Current CAH Treatment Paradigm in Children, Adolescents ...